ICML

Regulatory Applications Accepted in the U.S. and Japan for Bristol Myers Squibb’s Breyanzi (lisocabtagene maraleucel) in Relapsed or Refractory Follicular Lymphoma (FL) and Relapsed or Refractory Mantle Cell Lymphoma (MCL)

Retrieved on: 
Tuesday, January 30, 2024

In the U.S., the FDA has accepted the company’s two supplemental Biologics License Applications (sBLA) for Breyanzi to expand into new indications to include the treatment of adult patients with relapsed or refractory follicular lymphoma (FL) and relapsed or refractory mantle cell lymphoma (MCL) after a Bruton tyrosine kinase inhibitor (BTKi).

Key Points: 
  • In the U.S., the FDA has accepted the company’s two supplemental Biologics License Applications (sBLA) for Breyanzi to expand into new indications to include the treatment of adult patients with relapsed or refractory follicular lymphoma (FL) and relapsed or refractory mantle cell lymphoma (MCL) after a Bruton tyrosine kinase inhibitor (BTKi).
  • The FDA has granted both applications Priority Review and assigned a Prescription Drug User Fee Act (PDUFA) goal date of May 23, 2024 for Breyanzi in relapsed or refractory FL and May 31, 2024 for Breyanzi in relapsed or refractory MCL.
  • Japan's MHLW has also accepted Bristol Myers Squibb’s supplemental New Drug Application (sNDA) for Breyanzi for the treatment of relapsed or refractory FL.
  • In both studies, Breyanzi demonstrated a consistent safety profile with no new safety signals reported.

Allogene Therapeutics Reports Third Quarter 2023 Financial Results and Business Update

Retrieved on: 
Thursday, November 2, 2023

Following the close of the third quarter, the Company announced Geoffrey Parker as Executive Vice President, Chief Financial Officer, overseeing the Company’s financial operations and business development activities.

Key Points: 
  • Following the close of the third quarter, the Company announced Geoffrey Parker as Executive Vice President, Chief Financial Officer, overseeing the Company’s financial operations and business development activities.
  • Research and development expenses were $46.0 million for the third quarter of 2023, which includes $6.7 million of non-cash stock-based compensation expense.
  • General and administrative expenses were $17.0 million for the third quarter of 2023, which includes $8.6 million of non-cash stock-based compensation expense.
  • Allogene will host a live conference call and webcast today at 2:00 p.m. Pacific Time / 5:00 p.m. Eastern Time to discuss financial results and provide a business update.

Allogene Therapeutics Announces Poster Presentations at the 65th Annual Meeting of the American Society of Hematology

Retrieved on: 
Thursday, November 2, 2023

“All CAR T cells require lymphodepletion to support the expansion and persistence needed to eradicate malignant cells.

Key Points: 
  • “All CAR T cells require lymphodepletion to support the expansion and persistence needed to eradicate malignant cells.
  • Data from the 12 patients, a subset of these 33 CAR T naïve patients, who received the regimen being utilized in ongoing Phase 2 trials was presented at the American Society of Clinical Oncology (ASCO) Annual Meeting.
  • This study compared expansion kinetics among 11 allogeneic CAR T recipients treated with investigational ALLO-501A in the ALPHA2 trial.
  • Results of this study could help define strategies to improve allogeneic CAR T expansion, persistence, and efficacy.

NTT Research PHI Lab Scientists Address Bias in AI

Retrieved on: 
Tuesday, September 12, 2023

NTT Research, Inc. , a division of NTT (TYO:9432), today announced that scientists affiliated with its Physics & Informatics (PHI) Lab have co-authored a paper that proposes a way to overcome bias in deep neural networks (DNNs).

Key Points: 
  • NTT Research, Inc. , a division of NTT (TYO:9432), today announced that scientists affiliated with its Physics & Informatics (PHI) Lab have co-authored a paper that proposes a way to overcome bias in deep neural networks (DNNs).
  • “Our PHI Lab scientists and their colleagues have enlarged our understanding of the relatively neglected field of neural network fine-tuning in this notable paper and have proposed an innovative remedy for correcting against bias,” PHI Lab Director Yoshihisa Yamamoto said.
  • In a recent three-month span, top academic journals accepted or published a dozen papers co-authored by PHI Lab scientists.
  • The PHI Lab also has reached joint research agreements with numerous institutions, Harvard University being the most recent.

EQS-News: MorphoSys AG Reports Second Quarter and First Half 2023 Financial Results

Retrieved on: 
Wednesday, August 9, 2023

Minjuvi royalty revenue of € 2.2 million for sales outside of the U.S. in the second quarter 2023 and € 2.9 million for the first half of 2023.

Key Points: 
  • Minjuvi royalty revenue of € 2.2 million for sales outside of the U.S. in the second quarter 2023 and € 2.9 million for the first half of 2023.
  • The MorphoSys AG Annual General Meeting on May 17, 2023 re-elected Mr. George Golumbeski, Ph.D., and Mr. Michael Brosnan to the Company’s Supervisory Board.
  • Events After the End of the Second Quarter of 2023:
    On August 1, 2023, Incyte announced the full enrollment of the Phase 3 study inMIND.
  • Total revenues for the second quarter 2023 were € 53.2 million compared to € 59.4 million for the same period in 2022.

C4 Therapeutics Reports Second Quarter 2023 Financial Results and Recent Business Highlights

Retrieved on: 
Tuesday, August 8, 2023

WATERTOWN, Mass., Aug. 08, 2023 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science to develop a new generation of small-molecule medicines and transform how disease is treated, today reported financial results for the second quarter ended June 30, 2023, as well as recent business highlights.

Key Points: 
  • Revenue: Total revenue for the second quarter of 2023 was $2.7 million, compared to $13.8 million for the second quarter of 2022.
  • Research and Development (R&D) Expense: R&D expense for the second quarter of 2023 was $29.9 million, compared to $31.3 million for the second quarter of 2022.
  • General and Administrative (G&A) Expense: G&A expense for the second quarter of 2023 was $10.3 million, compared to $9.9 million for the second quarter of 2022.
  • Net loss per share for the second quarter of 2023 was $0.73 compared to $0.56 for the second quarter of 2022.

Allogene Therapeutics Reports Second Quarter 2023 Financial Results and Business Update

Retrieved on: 
Wednesday, August 2, 2023

Research and development expenses were $62.0 million for the second quarter of 2023, which includes $6.9 million of non-cash stock-based compensation expense.

Key Points: 
  • Research and development expenses were $62.0 million for the second quarter of 2023, which includes $6.9 million of non-cash stock-based compensation expense.
  • General and administrative expenses were $18.5 million for the second quarter of 2023, which includes $9.7 million of non-cash stock-based compensation expense.
  • Net loss for the second quarter of 2023 was $78.0 million, or $0.53 per share, including non-cash stock-based compensation expense of $16.6 million.
  • Allogene will host a live conference call and webcast today at 2:00 p.m. Pacific Time / 5:00 p.m. Eastern Time to discuss financial results and provide a business update.

Recursion Launches Valence Labs at ICML with a Commitment to Open Science Including $1 Million in Academic Scholarships

Retrieved on: 
Wednesday, July 26, 2023

SALT LAKE CITY, July 26, 2023 (GLOBE NEWSWIRE) -- Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, today launched Valence Labs at the International Conference on Machine Learning (ICML).

Key Points: 
  • SALT LAKE CITY, July 26, 2023 (GLOBE NEWSWIRE) -- Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, today launched Valence Labs at the International Conference on Machine Learning (ICML).
  • Valence Labs will serve as a machine learning research laboratory focused on developing the next generation of cutting-edge methods and models for drug discovery and consists of the emerging ML research teams at Recursion and the team at Valence Discovery, which Recursion recently acquired.
  • "Recursion believes in the power of open-science initiatives and wants to invest in rising talent and academic collaborations.
  • We are also committed to upholding our legacy of contributing significant datasets and tools for research purposes," said Chris Gibson, Ph.D., Co-founder and CEO of Recursion.

Cleanlab Emerges with $5 million to Automate Data Curation for LLMs and the Modern AI Stack

Retrieved on: 
Thursday, July 20, 2023

The flagship product, Cleanlab Studio , is the only enterprise solution for evaluating and correcting errors in both large structured data (e.g.

Key Points: 
  • The flagship product, Cleanlab Studio , is the only enterprise solution for evaluating and correcting errors in both large structured data (e.g.
  • Cleanlab automates data curation and correction to produce more accurate models in less time,” said Cleanlab AI co-founder & CEO Curtis Northcutt.
  • In 2022, Cleanlab published 5 peer-reviewed papers NeurIPS and ICML conferences/workshops and in 2023, Cleanlab’s executive team taught MIT’s course on Data-centric AI .
  • Visit Cleanlab Studio to learn more about Cleanlab’s no-code automated enterprise AI platform for data correction.

Nurix Therapeutics Reports Second Quarter Fiscal 2023 Financial Results and Provides a Corporate Update

Retrieved on: 
Thursday, July 13, 2023

SAN FRANCISCO, July 13, 2023 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical stage biopharmaceutical company developing targeted protein modulation drugs designed to treat patients with hematologic malignancies and solid tumors, today reported financial results for the fiscal quarter ended May 31, 2023, and provided a corporate update.

Key Points: 
  • Nurix also presented preclinical data demonstrating the potential utility of NX-5948 in addressing the unmet need in patients with central nervous system (CNS) lymphoma.
  • Nurix anticipates presenting additional clinical results from this ongoing trial in the second half of 2023.
  • Nurix also anticipates defining a regulatory strategy for NX-2127 in the second half of 2023 based on emerging clinical data and feedback from the FDA.
  • Cash, cash equivalents and marketable securities was $308.6 million as of May 31, 2023, compared to $325.6 million as of February 28, 2023.